Ipamorelin Dosage Guide: Timing, Cycling, and Growth Hormone Protocols

Ipamorelin Dosage Guide: Timing, Cycling, and Growth Hormone Protocols

Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist that stimulates the pituitary gland to release growth hormone (GH) in a pulsatile, physiological pattern. Unlike earlier growth hormone releasing peptides (GHRPs) such as GHRP-2 and GHRP-6, ipamorelin has a highly specific mechanism that avoids the unwanted side effects of cortisol and prolactin elevation. This selectivity makes it one of the most widely used GH peptides for body composition, recovery, and anti-aging purposes.

This guide covers ipamorelin dosing, timing, cycling, and how to stack it with CJC-1295 for amplified GH release.

How Ipamorelin Works

Ipamorelin mimics ghrelin and binds to the GHS-R1a receptor in the pituitary gland, triggering a pulse of endogenous growth hormone. Crucially, it does so without significantly elevating cortisol, aldosterone, acetylcholine, or prolactin — side effects associated with GHRP-2 and GHRP-6.

Key effects of elevated GH pulses from ipamorelin include:

• Increased IGF-1 production in the liver
• Enhanced lipolysis (fat breakdown)
• Improved muscle protein synthesis
• Better sleep quality and recovery
• Bone density support
• Anti-aging effects on skin and connective tissue

Ipamorelin has a short half-life of approximately 2 hours, so it acts as a pulse trigger rather than a sustained GH elevator.

Standard Ipamorelin Dosage

The standard dosage range is 100–300 mcg per injection, administered 2–3 times per day.

Conservative protocol (sleep, recovery, anti-aging):

• 100–150 mcg before bed only (1x daily)

Moderate protocol (body composition and recovery):

• 200 mcg 2x daily (morning fasted + before bed)

Aggressive protocol (advanced users, muscle building):

• 200–300 mcg 3x daily (morning fasted, post-workout, before bed)

Most users start with 100–200 mcg once daily before bed and add additional doses once they have assessed their response. There is limited evidence that doses above 300 mcg per injection provide proportionally greater GH release, as receptor saturation may occur.

Optimal Timing for Ipamorelin Injections

Timing is critical for maximizing the GH pulse from ipamorelin. Two windows offer the greatest benefit:

Before Bed (Most Important Dose)

The largest natural GH pulse of the day occurs in the first 1–2 hours of deep sleep. Administering ipamorelin 15–30 minutes before sleep amplifies this existing pulse, resulting in substantially higher total GH release overnight.

Protocol: Inject 200–300 mcg subcutaneously 15–30 minutes before sleep, ideally 2–3 hours after the last meal (fasted state preferred).

Fasted Morning

Taking ipamorelin in a fasted state (upon waking, before eating) capitalizes on low circulating insulin levels, which can blunt GH release. Low insulin = maximal GH response.

Protocol: Inject 100–200 mcg upon waking, then wait 20–30 minutes before eating breakfast.

Post-Workout (Optional Third Dose)

Exercise, particularly resistance training, creates a natural GH surge. A third ipamorelin injection 30–60 minutes after training can amplify this post-exercise GH peak.

Protocol: Inject 100–200 mcg 30–60 minutes after training.

Why Fasting Matters

Insulin and growth hormone have opposing effects and directly inhibit each other's signaling. Elevated insulin — as occurs after carbohydrate-rich meals — significantly blunts the GH-releasing effect of ipamorelin. Administering ipamorelin when insulin is low (fasted state) maximizes the resulting GH pulse by 2–3x compared to post-meal administration.

Rule: Wait at least 2 hours after eating (preferably 3 hours) before injecting ipamorelin. After injecting, wait 20–30 minutes before eating.

Ipamorelin Cycling: 8–12 Weeks On, 4 Weeks Off

Ipamorelin is not typically run continuously indefinitely. Cycling preserves pituitary sensitivity, prevents potential downregulation of GHS receptors, and allows assessment of response between cycles.

Standard cycle:

• On-cycle duration: 8–12 weeks
• Off-cycle duration: 4 weeks minimum

Conservative cycling:

• 8 weeks on / 4 weeks off (suitable for beginners)

Moderate cycling:

• 12 weeks on / 4 weeks off (advanced users)

Long cycle:

• 16–20 weeks on / 6–8 weeks off (with regular IGF-1 monitoring)

During off-weeks, some practitioners use a lower "maintenance" dose (50–100 mcg before bed only) rather than stopping completely, though this is not evidence-based and reduces the benefit of receptor rest.

Ipamorelin + CJC-1295: The Gold Standard Stack

Ipamorelin is almost universally stacked with CJC-1295 (without DAC) because the two peptides work through complementary mechanisms:

• Ipamorelin (GHRP): Acts on ghrelin receptors to trigger pituitary GH release
• CJC-1295 no-DAC (GHRH): Acts on GHRH receptors to amplify the signal

Together they produce a synergistic "double stimulation" of pituitary GH cells, resulting in 2–5x greater GH release than either peptide alone. This combination is the most widely cited protocol for GH optimization.

Typical combination dose:

• CJC-1295 (no-DAC): 100–200 mcg + Ipamorelin: 100–200 mcg, in the same injection

Most users combine them in a single syringe since both are reconstituted peptides injected subcutaneously. The combination can be dosed 1–3x daily following the same timing principles as ipamorelin alone.

Administration: Subcutaneous Injection

Ipamorelin is almost exclusively administered subcutaneously.

Sites: Abdomen (preferred), thigh, upper arm Needle: 27–30 gauge, 0.5 inch insulin syringe Technique: Pinch skin fold, insert at 45-degree angle, inject slowly over 5–10 seconds Rotation: Rotate injection sites to prevent lipohypertrophy

Reconstitution:

1. Add bacteriostatic water slowly to lyophilized powder
2. Common concentration: 2 mg per 2 mL (1 mg/mL) — each 0.1 mL = 100 mcg
3. Refrigerate after reconstitution; use within 28–30 days

Monitoring IGF-1 Levels

Because ipamorelin works primarily through elevating GH (which in turn raises IGF-1), serum IGF-1 is the most useful biomarker to track response.

Baseline: Test serum IGF-1 before starting Mid-cycle: Retest at 6–8 weeks to assess response Target range: IGF-1 in the upper quartile of the age-appropriate reference range (not above normal)

Excessive IGF-1 elevation (well above the normal range for age) is a signal to reduce dose or frequency. IGF-1 above the normal range for extended periods carries theoretical risks related to cell proliferation.

Expected Results and Timeline

Weeks 1–2: Improved sleep quality, more vivid dreams (marker of GH pulse during sleep), mild increase in energy

Weeks 3–4: Noticeable improvements in recovery, reduced soreness, potential skin texture improvements

Weeks 6–8: More significant body composition changes (lean muscle gains, reduction in body fat, particularly visceral), improved joint health

Full cycle (12 weeks): Measurable changes in IGF-1 levels, sustained improvements in body composition and recovery

Results are dose-dependent, training and nutrition-dependent, and are most pronounced in individuals with below-average baseline GH/IGF-1 levels.

Side Effects and Safety

Ipamorelin has one of the best safety profiles among GH secretagogues due to its selectivity:

Common (mild):

• Temporary water retention in early weeks
• Mild injection site discomfort
• Increased appetite (less than GHRP-6, generally mild)
• Tingling sensations (similar to carpal tunnel)

Uncommon:

• Headache (usually dose-related)
• Temporary fatigue on starting

Ipamorelin does NOT significantly elevate: cortisol, prolactin, aldosterone — the main advantages over GHRP-2/GHRP-6

Contraindications: Active cancer or history of cancer (GH elevation promotes IGF-1 which may be pro-proliferative), pregnancy, pediatric use, uncontrolled diabetes (GH raises blood glucose).

Frequently Asked Questions

Q: Should I take ipamorelin every day or can I take breaks within a cycle? Daily use during an on-cycle period is standard. Some protocols suggest 5 days on, 2 days off (weekdays only) to reduce cost and extend pituitary sensitivity. Both approaches are used; daily dosing is more common in research protocols.

Q: How long until I notice results from ipamorelin? Sleep improvements and recovery benefits are often noticed within 1–2 weeks. Body composition changes take 6–12 weeks of consistent use combined with appropriate training and nutrition.

Q: Can I take ipamorelin with food? You can, but it significantly blunts the GH response. Insulin from meals inhibits GH secretion. For maximum effect, always inject ipamorelin in a fasted state (2–3 hours after eating) and wait 20–30 minutes before your next meal.

Q: What is the difference between ipamorelin and sermorelin? Sermorelin is a GHRH analog (like CJC-1295) that acts on GHRH receptors. Ipamorelin is a GHRP that acts on ghrelin receptors. They stimulate GH through different receptor pathways and are synergistic when combined. Sermorelin is FDA-approved and often used in anti-aging medicine; ipamorelin is a research peptide.

Q: Is ipamorelin detectable in drug tests? Ipamorelin is prohibited by WADA in competitive sport. Standard clinical drug tests do not screen for peptides, but sports-specific doping tests may. Competitive athletes should not use ipamorelin without understanding their sport's prohibited substance list.

Q: How do I know if my ipamorelin is working? The most reliable indicators are: improved deep sleep quality, increased overnight recovery, elevated IGF-1 on blood work, and gradual changes in body composition over 8–12 weeks. A blunted response may indicate suboptimal timing (eating too close to injection), poor peptide quality, or the need for a stacked GHRH like CJC-1295.

---

This article is for informational purposes only. Ipamorelin is not FDA-approved for human therapeutic use outside of research contexts. Consult a healthcare provider before beginning any peptide protocol.